Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke

INTRODUCTION: Stroke is a common cause of epilepsy that may be mediated via glutamate dysregulation. There is currently no evidence to support the use of antiseizure medications as primary prevention against poststroke epilepsy. Perampanel has a unique antiglutamatergic mechanism of action and may h...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Open
Auteurs principaux: Nicolo, John-Paul, Chen, Zhibin, Moffat, Bradford, Wright, David K, Sinclair, Benjamin, Glarin, Rebecca, Neal, Andrew, Thijs, Vincent, Seneviratne, Udaya, Yan, Bernard, Cloud, Geoffrey, O'Brien, Terence J, Kwan, Patrick
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2021
Sujets:
Neurology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8112439/
https://ncbi.nlm.nih.gov/pubmed/33972334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-043488
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires